Elastic vesicles for enhancing the transdermal delivery of Olmesartan Medoxomil | ||||
| Bulletin of Pharmaceutical Sciences Assiut University | ||||
| Articles in Press, Accepted Manuscript, Available Online from 27 July 2024 | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bfsa.2024.294767.2150 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
reem Al-Uobody  1; Thair L. Jabbar2; amira amin3
| ||||
| 1Department of Pharmacy, Mazaya University College, Thi-Qar, Iraq. | ||||
| 2College of Pharmacy,Al-Ayen University,Iraq | ||||
| 3Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhour university, Damanhour, Egypt | ||||
| Abstract | ||||
| Hypertension seems to be a disorder that needs consideration for developing a transder mal drug delivery system (TDDS) because it requires long and continuing therapy. Olmesartan Medoxomil is an antihypertensive medication which has substantial first pass metabolism results in low oral bioavailability. In order to prevent oral complications, the production of elastic vesicles for improving Olmesartan Medoxomil transdermal distribution was the focus of this paper's study. Using a 21.31 full factorial design and a range of edge activators in varying quantities, elastic vesicles formulas were created. The formulae's zeta potential (ZP), particle size (PS), polydispersity index (PDI), entrapment efficiency percentage (EE%), and amount of drug released after six hours (Q6h) were all described. Utilizing Design Expert® software, the ideal formula (F4) was determined, revealing EE% of 81.00±1.22%, PS of 287.30±1.43 nm, PDI of 0.18±0.03, ZP of -39.61±1.10 mV, and Q6h of 47.15±1.10%. The histological investigation verified the safety of the optimum elastic vesicles. | ||||
| Keywords | ||||
| Olmesartan Medoxomil; elastic vesicles; factorial design; transdermal drug delivery | ||||
|
Statistics Article View: 85 |
||||
